Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 55

Results For "ISO"

1345 News Found

India emerging as world-class cost-effective healthcare destination and global pharma leader: Dr. Jitendra Singh
Policy | August 07, 2024

India emerging as world-class cost-effective healthcare destination and global pharma leader: Dr. Jitendra Singh

He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries


Lupin completes  successful Phase 3 trials for Lucentis biosimilar
Biotech | August 06, 2024

Lupin completes successful Phase 3 trials for Lucentis biosimilar

The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU


AbbVie completes acquisition of Cerevel Therapeutics
News | August 03, 2024

AbbVie completes acquisition of Cerevel Therapeutics

Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia


DGHS conducts meeting on health promotion, healthy campus initiative and tobacco control
Policy | August 01, 2024

DGHS conducts meeting on health promotion, healthy campus initiative and tobacco control

More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options


American Oncology Institute (AOI) Nagpur conducts two consecutive successful bone marrow transplants
News | July 31, 2024

American Oncology Institute (AOI) Nagpur conducts two consecutive successful bone marrow transplants

Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection


Mankind Pharma to acquire 100% stake in Bharat Serums from Advent for Rs. 13,630 Cr
News | July 26, 2024

Mankind Pharma to acquire 100% stake in Bharat Serums from Advent for Rs. 13,630 Cr

Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands


Pfizer announces positive topline results from Phase 3 study of hemophilia A gene therapy candidate
Clinical Trials | July 26, 2024

Pfizer announces positive topline results from Phase 3 study of hemophilia A gene therapy candidate

Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis


European Commission approves Pfizer’s Durveqtix gene therapy for adults with hemophilia B
Drug Approval | July 26, 2024

European Commission approves Pfizer’s Durveqtix gene therapy for adults with hemophilia B

A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)


Fostering closer ties between industry & academia imperative for sustainable growth
News | July 25, 2024

Fostering closer ties between industry & academia imperative for sustainable growth

The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future